Lung cancer is the leading cause of cancer death worldwide. Low-dose computed tomography screening (LDCT) was recently shown to anticipate the time of diagnosis, thus reducing lung cancer mortality. However, concerns persist about the feasibility and costs of large-scale LDCT programs. Such concerns may be addressed by clearly defining the target "highrisk" population that needs to be screened by LDCT. We recently identified a serum microRNA signature (the miR-Test) that could identify the optimal target population. Here, we performed a large-scale validation study of the miR-Test in highrisk individuals (n = 1115) enrolled in the Continuous Observation of Smoking Subjects (COSMOS) lung cancer screening program. The overall accuracy, sensitivity, and specificity of the miR-Test are 74.9% (95% confidence interval [CI] = 72.2% to 77.6%), 77.8% (95% CI = 64.2% to 91.4%), and 74.8% (95% CI = 72.1% to 77.5%), respectively; the area under the curve is 0.85 (95% CI = 0.78 to 0.92). These results argue that the miR-Test might represent a useful tool for lung cancer screening in highrisk individuals. brief communication * The median risk score with first and third quartile in parentheses (Q1;Q3) are indicated. AUC = area under the curve; CI = confidence interval; COPD = patients with chronic obstructive pulmonary disease; CT = computed tomography; NOD = patients with low-dose computed tomography-detected, noncalcified, lung nodules stable in size at more than five years of follow-up; PN = patients with pneumonia. † The 95% confidence interval is reported in the parentheses.. ‡ Two individuals with both PN and COPD. § Individuals without lung cancer with more than five years of screening follow-up.
Single-arm and randomized studies have shown that low-dose computed tomography (LDCT) allows early detection of lung cancer in high-risk individuals and reduces disease-related mortality (1, 2) . Its cost-effectiveness has also been recently described (2) (3) (4) (5) . In principle, the refinement of the preselection criteria based on additional risk factors, such as blood tumor markers, might promote the implementation of widespread LDCT screening and improve its cost-effectiveness. MicroRNAs (miRNAs), short noncoding RNAs involved in cellular regulation (6, 7) , represent promising blood-borne tumor markers. The expression of miRNAs is often deregulated in tumors, leading to alterations in miRNA profiles in bodily fluids, including serum and plasma (8) (9) (10) (11) (12) (13) . Thus, the detection of circulating miRNAs might be useful for lung cancer early detection, as recently suggested (14) .
We designed a multi-tiered study to validate a blood test based on serum miRNAs (12) in high-risk individuals (heavy smokers, older than age 50 years) enrolled in the Continuous Observation of Smoking Subjects (COSMOS) trial (15) and lung cancer patients diagnosed outside of the screening ( Figure 1A ).
Informed consent was obtained from all participants after institutional review board approval of the study. Details on blood collection, serum analysis, expression profiling, and other methods are described in the Supplementary Methods (available online).
Initially, we refined our original 34-miRNA signature (12) using a "Calibration set" of 24 subjects (Table 1; Supplementary  Tables 1 and 2, available online) . This refinement allowed a reduction of the signature to 13 miRNAs (henceforth, the miR-Test: miR-92a-3p, miR-30b-5p, miR-191-5p, miR-484, miR-328-3p, miR-30c-5p, miR-374a-5p, let-7d-5p, miR-331-3p, miR-29a-3p, miR-148a-3p, miR-223-3p, miR-140-5p), which maintained the same performance as the original signature (Corr. ≥ 0.96) ( Supplementary Figure 1 , available online). The refinement of the signature reduces the costs and complexity of the test and increases its clinical translatability.
The miR-Test was then validated in an independent "Validation Set" of 1008 subjects enrolled in the COSMOS trial ( Figure 1A ; Supplementary Table 1 , available online). Overall, risk scores between this set of lung cancer patients and healthy subjects were statistically significantly different (P < .001), as we observed in the Calibration Set ( Figure 1B and Table 1 ; Supplementary Table 2 , available online). In the Validation Set, the test displayed an area under the curve (AUC) of 0.85 (95% CI = 0.78 to 0.92) and an accuracy (ACC), sensitivity (SE) and specificity (SP) of 74.9% (95% CI = 72.2% to 77.6%), 77.8% (95% CI = 64.2% to 91.4%), and 74.8% (95% CI = 72.1% to 77.5%), respectively ( Figure 1C and Table 1 ). Next, we assessed the ability of the miR-Test to distinguish between nonmalignant lung diseases (NMD) and lung cancer in an independent cohort of individuals with chronic obstructive pulmonary disease (COPD), Figure 1A) , for whom a long follow-up period was available (more than five years) (Supplementary Table 1 , available online). In this set, 72 out of 83 (86.7%) individuals were miR-Test negative ( Figure 1D and Table 1 ). Of note, five of five patients surgically treated for a benign tumor were miR-Test negative ( Figure 1D and Table 1 ). Similar results were obtained in individuals with COPD or with pneumonia selected within the "Validation Set" ( Figure 1D and Table 1 ). We then applied the miR-Test to a third independent set, the "Clinical Set", composed of lung cancer patients diagnosed outside of the COSMOS trial ( Figure 1E and Table 1 ). This analysis allowed us to evaluate sensitivity of miR-Test in an unselected population harboring more advanced lung cancers (Stage II to III), which are normally underrepresented among screen-detected tumors (Supplementary Table 1 , available online). The sensitivity in Clinical Set was comparable with that in the Validation Set (sensitivity [SE] = 70.3%, 95% confidence interval [CI] = 59.9% to 80.7%) ( Table 1 ). No major differences were observed in the sensitivity of detection of different tumor stages (Stage I, SE = 69.0%, 95% CI = 55.1% to 83.0%; Stage II to III, SE = 71.9%, 95% CI = 56.3% to 87.5%) ( Table 1) or subtypes (P = .56) ( Figure 1E ). Finally, we analyzed serum samples of patients with Stage I non-small cell lung cancer (NSCLC) before and after surgery. At one month postsurgery, we did not observe a statistically significant decrease in the miR-Test risk scores (P = .33) ( Figure 1F ). In some patients the risk increased in the absence of any residual disease, possibly from the release of stable miRNAs as a consequence of surgery. There was, differently, a statistically significant decrease in most patients at five months postsurgery (P = .02) ( Figure 1F ). In two patients, whose sera were available at 12 months postsurgery, the miR-Test risk score continued to decrease with respect to the five-month risk score and yielded a negative test result in both cases ( Figure 1F ). Similar results were obtained using the original 34-miRNA-signature ( Supplementary Figure 1, available online) .
Recently, the Centers for Medicare and Medicaid Services (CMS) proposed coverage of the costs of an annual LDCT scan for high-risk beneficiaries (16) . The availability of blood-detectable markers for selecting a high-risk population for subsequent LDCT screening could help reduce screening costs and increase compliance. Our miR-Test possesses the characteristics of accuracy and robustness required for such a first-line tool. In the COSMOS cohort analyzed in this study (the Calibration, Validation, and Specificity Sets), the test reached a sensitivity of 79.2% (95% CI = 67.7% to 90.7%) and a specificty of 75.9% (95% CI = 73.3% to 78.5%) ( Table 1) . Overall, 820 out of the 1115 individuals were miR-Test negatives (73.5%), including 810 out of the 1067 individuals without lung cancer and 10 of the 48 individuals with lung cancer ("ALL [CT screening]") ( Table 1 ). The negative predictive value (NPV) was greater than 99%, meaning that negative-risk individuals can safely avoid subsequent LDCT scan. The sensitivity and NPV of miR-Test are comparable with LDCT alone (2, 15, 17) , indicating that the miR-Test could be used as a first-line screening tool. Conversely, the lower specificity of the test compared with LDCT would not affect the overall screening result, as miR-Test-positive cases would undergo LDCT to confirm diagnosis and localize neoplastic lesions for subsequent surgery. Notably, most individuals with NMD (126 out of 164, 76.8%) were miR-Test negative. This is relevant because in LDCT screening trials there is a high rate of false-positive findings, up to 28% (2, 15) . Therefore, a first-line screening miR-Test could considerably reduce unnecessary LDCTs for individuals without lung cancer.
A limit of the present study is that validation of miR-Test was monocentric. We therefore launched, in 2012, a new Italian multicentric lung cancer screening trial (COSMOS II study), enrolling approximately 10 000 high-risk subjects from eight different health institutions. Individuals will be screened by both CT and miR-Test.
Other miRNA-signatures were recently proposed for lung cancer detection (18) . Of these, only two signatures were validated in actual lung cancer screening studies (14, 19) . In particular, the MSC classifier based on plasma miRNAs (14) , validated in a large lung cancer screening trial (MILD study), displays an overlap of five miRNAs with our miR-Test (38.5%). This represents an encouraging comparison, given the low overlap generally observed among similar signatures (20, 21) and the differences in miRNA quantities and species between serum and plasma (22) (23) (24) (25) . A prospective analysis of the two signatures in the same cohorts of individuals could reveal whether, together, they can synergize towards increased diagnostic accuracy.
Notes
The study funders had no role in the design of the study, the collection, analysis, or interpretation of the data, the writing of the manuscript, nor the decision to submit the manuscript for publication. PPDF is the recipient of a sponsored research fund for the development of diagnostic miRNA-based blood signatures from a privately held molecular diagnostic company (Gensignia Life Sciences, Inc.). The research fund in object was conferred after the termination of the experimental work herein described. In addition, MJM, FN, PPDF, and FB are coinventors on a patent application regarding the diagnostic miRNA-based blood signatures described herein. We are indebted to: Maria Capra and Daniela Brambilla for the selection of samples and the collection of patients' clinical and pathological information; Davide Proverbio, Giulio Taliento, Andrea Uggetti, and Maria Lucia Longo, for blood collection and sera preparation; Pascale R. Romano and Rosalind Gunby for critically editing the manuscript. We also thank the European Institute of Oncology (IEO) Biobank and Biomolecular Resource Infrastructure (IBBRI), the Division of Thoracic Surgery, the Division of Radiology, and the Division of Pathology at IEO.
